These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 37318408)
1. Adolescent COVID-19 Cases During the SARS-CoV-2 Delta and Omicron Variant Surges in Kentucky: Association With Vaccination and Prior Infection. Spicer KB; Glick C; Thoroughman DA J Adolesc Health; 2023 Sep; 73(3):536-542. PubMed ID: 37318408 [TBL] [Abstract][Full Text] [Related]
2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536 [TBL] [Abstract][Full Text] [Related]
3. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. Bozio CH; Butterfield KA; Briggs Hagen M; Grannis S; Drawz P; Hartmann E; Ong TC; Fireman B; Natarajan K; Dascomb K; Gaglani M; DeSilva MB; Yang DH; Midgley CM; Dixon BE; Naleway AL; Grisel N; Liao IC; Reese SE; Fadel WF; Irving SA; Lewis N; Arndorfer J; Murthy K; Riddles J; Valvi NR; Mamawala M; Embi PJ; Thompson MG; Stenehjem E J Infect Dis; 2023 Jun; 227(12):1348-1363. PubMed ID: 36806690 [TBL] [Abstract][Full Text] [Related]
4. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036 [TBL] [Abstract][Full Text] [Related]
5. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402 [TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
8. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946 [TBL] [Abstract][Full Text] [Related]
9. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
14. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis. Lind ML; Robertson AJ; Silva J; Warner F; Coppi AC; Price N; Duckwall C; Sosensky P; Di Giuseppe EC; Borg R; Fofana MO; Ranzani OT; Dean NE; Andrews JR; Croda J; Iwasaki A; Cummings DAT; Ko AI; Hitchings MDT; Schulz WL PLoS Med; 2022 Dec; 19(12):e1004136. PubMed ID: 36454733 [TBL] [Abstract][Full Text] [Related]
15. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007 [TBL] [Abstract][Full Text] [Related]
16. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults. Lee N; Nguyen L; Austin PC; Brown KA; Grewal R; Buchan SA; Nasreen S; Gubbay J; Schwartz KL; Tadrous M; Wilson K; Wilson SE; Kwong JC Clin Infect Dis; 2024 May; 78(5):1372-1382. PubMed ID: 38001037 [TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678 [TBL] [Abstract][Full Text] [Related]
19. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R; Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789 [TBL] [Abstract][Full Text] [Related]
20. Association of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or a Prior Positive Test Result in Adolescents during the Delta Variant Surge in Kentucky. Spicer KB; Glick C; Cavanaugh AM; Thoroughman D J Pediatr; 2022 Sep; 248():119-121. PubMed ID: 35644225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]